Nivolumab Plus Ipilimumab Extends TFS Over Nivolumab Alone in Advanced Melanoma

Source: Oncology Learning Network, 2020

With extended follow-up, patients with advanced melanoma given nivolumab plus ipilimumab were shown to have a treatment-free survival (TFS) twice as long as those given nivolumab monotherapy, according to data presented at the virtual 2020 ASCO Annual Meeting.

“We previously defined a novel outcome, TFS, to characterize the time between immune-checkpoint inhibitors (ICI) therapy cessation and subsequent therapy initiation/death,” explained Meredith M. Regan, ScD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, and co-investigators.

In 2019, Dr Regan et al reported on the TFS of ICI-treated patients with advanced melanoma in the 36 months after randomization in the phase 3 CheckMate-067 trial. At the virtual meeting, they presented TFS data for 937 patients in CheckMate-067 in the 60 months post-randomization.

READ THE ORIGINAL FULL ARTICLE